David P. Holveck, President
Johnson & Johnson Development Corp.; former CEO of Centocor

David P. Holveck is Corporate vice president, corporate development, for Johnson & Johnson and an officer of the Corporation.  He was named to his present position in March, 2004.  In addition, Mr. Holveck serves as president, Johnson & Johnson Development Corporation.  He was appointed to this position in March 2003.

Mr. Holveck joined the Corporation as a company group chairman in October 1999, with the completion of the merger of Centocor, Inc., and Johnson & Johnson.  Prior to joining Johnson & Johnson, he had been chief executive officer of Centocor, Inc., since 1992 and a member of its board of directors since 1994.

In 1983 Mr. Holveck started his Centocor, Inc., career, progressing through various executive positions.  In 1992 he assumed the role of president and chief operating officer of Centocor, Inc., and later that year was named president and chief executive officer.  In 2003 Mr. Holveck was promoted to president, Johnson & Johnson Development Corporation, a position he held until being named to his present assignment.

Prior to joining Centocor, Inc., he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.

Mr. Holveck is a board member of the University City Science Center in Philadelphia and the Eastern Technology Council.  He also serves on the Board of Trustees for The Fund for West Chester University.  Mr. Holveck is a former board member of the Biotechnology Industry Organization, Pharmaceutical Research and Manufacturing Association (PhRMA), the Board of Governors for Pennsylvania's State System of Higher Education and the Liberty Science Center

Mr. Holveck received a bachelor of science degree in education/science from West Chester University. He and his wife have two daughters and five grandchildren.

Paul H. Keckley, Ph.D.
Executive Director of the Deloitte Center for Health Solutions

Paul H. Keckley, Ph.D., is Executive Director for the Deloitte Center for Health Solutions (“the Center”), a part of Deloitte & Touche USA LLP.  He is a health economist and policy expert and brings a distinguished 30 year career in health services research in the private sector and academic medicine.

The Deloitte Center for Health Solutions is an independent research organization focused on the issues and challenges of the US health system. The Center’s research agenda includes trending of healthcare consumerism, monitoring of pay for performance programs, innovations in reducing the gap between evidence and practice, enhanced methods for information technology adoption, and models of community care coordination that improve population-based health status while reducing costs. 

Prior to joining Deloitte, Dr. Keckley served in several key roles at Vanderbilt University Medical Center’s senior management, including Executive Director of the Vanderbilt Center for Evidence-based Medicine, Associate Professor in the Vanderbilt University School of Medicine, and Adjunct Professor of Health Management at the Owen Graduate School of Business’ healthcare MBA and MD-MBA programs.

Before joining Vanderbilt, Dr. Keckley served as Chairman of the Board of Interdent, a California dental practice management company; Chief Executive Officer of EBM Solutions, a developer of evidence-based guideline software; Chief Executive Officer of Aveta; and Principal of The Keckley Group, a strategic planning consulting practice that served 1,200 U.S. provider organizations and health plans.  

Dr. Keckley is an active member of several societies and editorial boards, and has authored numerous articles and three books.  He has been profiled by ABC’s 20/20, CBS’s 60 Minutes, Fox News, CNN, and The Wall Street Journal.  Dr. Keckley received a B.A. from Lipscomb University, his MA/PhD from Ohio State University, and completed a fellowship in economic policy at Oxford University.

M&A Panel

Jim Boylan (’94)
Managing Director, Merrill Lynch

Jim joined Merrill Lynch in 1997 and is currently a Managing Director in the Global Healthcare Investment Banking Group. Prior to joining the healthcare group, Jim was a Managing Director in Merrill Lynch’s Mergers & Acquisitions Group specializing in Healthcare M&A. Jim has significant relationships and transaction experience across healthcare including services, medical devices and biotech/pharma. Recent equity experience includes the IPOs of Tomotherapy, Insulet and NxStage, follow-on offerings for Omnicare and Celgene and convertible offerings for MedImmune and Lincare. Jim’s M&A experience includes NxStage's acquisition of MediSystems, Healthway's acquisition of Axia Health, the sale of The F. Dohmen's wholesale distribution business to Cardinal Health, the sale of CRC Health to Bain Capital, the sale of Proxima Therapeutics to Cytyc, Advance Paradigm's acquisition of PCS HealthSystems, MedImmune's acquisition of Aviron and Allergan's spin-off of Advanced Medical Optics. Prior to joining Merrill Lynch, Jim was a healthcare investment banker at Smith Barney where he completed several debt and equity financing transactions. He received a B.S. in finance from Lehigh University in 1989 and an M.B.A. from Columbia Business School in 1994.

Tamar Howson (’80), Executive Vice President, Business Development, Lexicon Pharmaceuticals

Tamar Howson joined Lexicon Pharmaceuticals as Executive Vice President, Business development in April, 2007.  Between 2001 and 2007 Tamar was the Senior Vice President of Corporate and Business Development and member of the Executive Committee at Bristol-Myers Squibb. While at BMS, Tamar worked on many licensing agreements and research collaborations including partnerships with Lexicon, Medarex, Pierre-Fabre, Solvay, Exelixis, Merck, Astra-Zeneca among others.  

In 2000 and 2001 Tamar was a business development and strategic planning consultant to biotechnology and pharmaceutical companies, served as a Special Limited partner at Care Capital, LLC., a Director for Ariad Pharmaceuticals, NPS Pharmaceuticals, SkyePharma Plc., Targacept as well as on several advisory boards.  Between 1991 and 2000, Ms. Howson was the Senior Vice President and Director of Worldwide Business Development for SmithKline Beecham.  During her tenure at SB, she and her team signed numerous in- and out-licensing agreements and research collaborations.  Between 1998 and 2000 she also managed SB’s $100MM venture capital fund, SR One, the Corporate Development team, and was a member of the Corporate Management Team.  Between 1991 and 1993, she served as Vice President and Director, Worldwide Business Development for SmithKline.  Before joining SmithKline, Tamar was Vice President, Venture Investments at Johnston Associates, a venture capital firm.  Before that, she was Director of Worldwide Business Development and Licensing for Squibb Corporation.  

Ms. Howson holds a Masters of Business Administration from Columbia University, a Masters of Science from City College of New York and Bachelors of Science in Chemical Engineering from the Technion in Israel. 

Perry Karsen, Senior Vice President, Business Development, Celgene

Perry Karsen is Senior Vice President, Business Development at Celgene Corporation responsible for Celgene’s business development, licensing and strategic collaboration initiatives.  Perry joined Celgene from Human Genome Sciences where he was Senior Vice President, Business Development.  

Perry began his career as a product manager at Abbott Laboratories.  He was promoted through several positions within product and general management, including assignments in Japan and Europe, and then moved into the role of Director, Licensing and Acquisitions.  Perry assumed the role of Director, Business Development and Representative Director, Japan at Genentech where he identified and negotiated numerous business development relationships in the genomics, drug delivery and development and combinatorial chemistry areas.  Perry then joined Bristol-Myers Squibb where he held positions as Vice President, Strategic Business Analysis and Development, Vice President, Corporate Development, and Senior Vice President, Marketing & Sales, Zimmer, Inc.  Perry went on from Bristol-Myers Squibb to become a General Partner of Pequot Ventures, where he was responsible for early- and late-stage healthcare investments in biotechnology and medical devices.  

Perry has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana.  In addition, Perry has over 20 years of pharmaceutical and biotechnology industry experience.  

Dan Tully, Managing Director, Altaris Capital Partners

Mr. Tully is a founding partner of Altaris with responsibility for sourcing, analyzing, executing and monitoring private equity transactions. Prior to the formation of Altaris, Mr. Tully held various positions with Merrill Lynch, including serving as the firm’s global head of healthcare equity capital markets. Mr. Tully was previously a member of Merrill Lynch’s private equity and investment banking groups. Mr. Tully received a B.S. in Economics from the University of Pennsylvania, Wharton Undergraduate Program.

Mr. Tully is currently a board member of the following Altaris portfolio companies: Alterna, Brim Healthcare, Creganna Limited, JDS Pharmaceuticals, M2S and Sparta Systems. In addition, Mr. Tully serves as vice chairman of the board of the Hospital for Special Surgery in New York.


Costs/Outcomes Panel:

Karen Scott Collins, M.D., M.P.H
Vice President, Quality and Patient Safety, New York-Presbyterian Hospital

Dr. Collins joined NewYork Presbyterian Hospital in August 2007 as Vice President for Quality and Patient Safety. In this position, she is responsible for developing and leading clinical quality improvement and patient safety work across the five hospital campuses of the Columbia and Cornell Medical Schools. Immediately prior to this, she served as Deputy Chief Medical Officer, for the New York City Health and Hospitals.

Dr. Collins has published articles and reports on trends and experiences with managed care, women’s health, adolescent health and minority health.  She is the co-editor of two books, Women’s Health: The Commonwealth Fund Survey, and Minority Health in America, both published by Johns Hopkins University Press.  In April 2002, Dr. Collins received the Healthcare Hero award from the Congressional Black Caucus. Dr. Collins completed her undergraduate degree in History of Science at Harvard University, medical school at Cornell University Medical College, and master of public health degree at Bloomberg School of Public Health at Johns Hopkins University.   

Dr. Lorna Friedman
VP & Senior Medical Executive for National Accounts, CIGNA 

Dr. Friedman is currently Vice President and Senior Medical Executive in CIGNA Healthcare. She joined CIGNA in 1998 as Associate Medical Director and since then has grown through many leadership roles within CIGNA. In her current role, she is responsible for new business development and growth in multiple product lines including medical, dental, pharmacy, behavioral and health management. In addition to her stellar record as part of the sales team, she has innovated on disease management solution for some of CIGNA’s larger clients.

She is the clinical liaison in product for wellness and women and children’s programs: Healthy Kids Challenge, March of Dimes & Healthy Rewards. She has represented CIGNA in presenting the firm’s vision on Health Care and Consumerism attended by who’s who on Wall St’s sell-side and buy-side analysts. Dr. Friedman has an MBA from Columbia Business School and MD from New York Medical College.

Michael K. Gusmano
Assistant Professor of Health Policy and Management, Mailman School of Public Health

Dr. Michael Gusmano is the director of research for the Alliance for Health & the Future and co-director of the World Cities Project at the International Longevity Center-USA. Dr. Gusmano’s work has focused on comparing the health status and use of health and social services for older persons in such cities as New York, London, Paris, and Tokyo. His other research interests include politics of healthcare reform, Medicare, Medicaid, and comparative welfare state analysis. Prior to joining the ILC, Dr. Gusmano was a senior research associate in the Division of Health and Science Policy at the New York Academy of Medicine. Previously, he was a research associate in the Department of Epidemiology and Public Health, and a lecturer in the Department of Political Science at Yale University where he conducted research on healthcare politics and policy. Dr. Gusmano was a post-doctoral fellow in the Robert Wood Johnson Foundation Scholars in Health Policy program at Yale University.

J. Brent Pawlecki, MD, MMM
Corporate Medical Director, Pitney Bowes Inc.

Dr. Pawlecki serves as the Corporate Medical Director, overseeing all health related issues and services of the organization, including the Pitney Bowes' award-winning corporate clinics and wellness programs and the Absence Management Department. 

In addition, he serves as corporate medical consultant and as Chief HIPAA Privacy Officer.  Dr. Pawlecki works closely with the integrated functions of Disability, Safety, and Worker’s Compensation, as well as the Health Care Strategy Group and the Crisis Management Team to direct corporate health and productivity for the global organization.  Currently, he is heading the efforts of the global Pandemic Preparedness Team for the corporation.


Pharmaceutical Marketing Panel:

Moderator: Jacques Mulder
Principal, Deloitte Consulting

Jacques Mulder has been a Principal at Deloitte Consulting for 4 years in the Healthcare Life Sciences practice.  With years of consulting experience, Jacques has advised pharmaceutical and biotechnology companies, medical device manufacturers, healthcare associations, investment firms, and government organizations.  He has developed marketing strategies for new products, covering issues such as clinical development strategy, pricing, positioning, and economic evidence needed to support coverage and optimal payment.  Prior to Deloitte, Jacques served as the head of Quintiles Strategic Research Services, having responsibility for the Phase IIIb and Phase IV clinical operations, North America and Canada.  He joined Quintiles Strategic Research Services after having served as Senior Vice President of Quintiles Integrated Strategic Solutions, Quintiles’ medical communications and healthcare consulting unit.  In this capacity, Jacques was responsible for market and financial strategy and new business development where he was personally responsible for revenues in excess of $80M annually. 

Jacques has been integrally involved in many functional areas of the pharmaceutical industry including distribution management, strategic management, and informatics. He has extensive experience across the commercial aspects of the pharmaceutical industry having worked for several international pharmaceutical companies.  Jacques also has experience in many therapeutic areas including respiratory, gastrointestinal, and anti-infective pharmaceuticals and speaks frequently at seminars both to and for pharmaceutical companies. He is a member of the International Institute of Marketing Management and speaks at industry conferences for Frost and Sullivan, PMT, British Biotech Association and has served as a guest lecturer for EBS at some international events.  Jacques holds a Master of Business Administration from Edinburgh Business School and a Bachelor of Science in Physiology and Biomechanics from Clemson University and the University of Pretoria.

Robert Bazemore, Jr. 
VP Bio-Worldwide, Johnson & Johnson Pharma Services

Rob Bazemore, with over 16 years of pharmaceutical experience, has served as Worldwide Vice President - Immunology Franchise, WW Strategic Marketing for Johnson and Johnson Pharmaceutical Services, since 2005. In this role, Rob develops the business and portfolio strategy for the J&J Immunology Franchise, leading implementation of the strategy through Discovery, Clinical Research and Development, Business Development, and brand teams. Rob joined Centocor, and Johnson and Johnson company, in 2002 where he led the development and execution of the lifecycle strategy for REMICADE across therapeutic areas; in 2003, he accepted a position leading the marketing of REMICADE in Centocor's Rheumatology Franchise. 

Prior to Centocor, Rob worked for nearly 10  years at Merck  from 1991 – 2000. While at Merck, he broadened his understanding and leadership in pharmaceuticals through roles in field sales, then medical affairs, and both brand and strategic marketing. 

Rob holds an MBA from Tulane University and a B.A. in biochemistry from the University of Georgia.

Charles G. Beever
Vice President, Booz Allen Hamilton

Mr. Beever is a Vice President with Booz Allen Hamilton, with over 20 years of experience working with pharmaceutical and medical products companies to resolve strategic, organization and performance improvement issues.  He leads Booz Allen Hamilton’s worldwide pharmaceutical practice.

Mr. Beever has worked with U.S., European, and Japan-based pharmaceutical, biotechnology, diagnostic and medical device/supply companies on strategic issues involving business growth, diversification and acquisition due diligence.  He has also led major merger integration planning and implementation assignments.  In addition, he has helped health care companies redesign their operations and organizations to meet the needs of the evolving health care environment, yielding significant improvements in effectiveness and cost.

Mr. Beever holds a BA degree in economics from Haverford College, where he was elected to Phi Beta Kappa, and an MBA from the Harvard Graduate School of Business Administration.

Andreas Fibig
Senior Vice President, General Manager, Powers (CNS/APM), Pfizer

Andreas Fibig is a pharmaceutical industry business leader, with more than 20 years international experience, including executive responsibilities in North America, South America, Europe and Asia.  He has held senior positions across a broad range of disciplines, from product and brand management, to sales management, strategic marketing, and both country and continental leadership.

As Senior Vice President/General Manager, Powers – CNS/APM, Andreas is responsible for all of Pfizer’s central nervous system, neurology and pain management operations in the United States.  This business unit represents some $5 billion in annual revenues, and more than 4,000 Pfizer colleagues.

Prior to his appointment as a U.S. business unit head, Andreas served as President – Latin America/Africa/Middle East, and as Regional President – Latin America.  He had previously been President and Country Manager for Pharmacia in Germany, after rising through a series of progressively more senior roles, in Europe and internationally, for Pharmacia, Boehringer-Ingelheim and Schering.

Andreas places particular emphasis on long-term planning, innovation across all functional areas, and the establishment of ethical, mutually-beneficial partnerships with customers and health care stakeholders.  He has a record of generating successful results in both highly-competitive developed markets and emerging markets with limited resources.  Throughout his career, he has also devoted major investment and interest to people development, making the recognition, reward and promotion of talent a top priority – and a key success factor - among his teams.

Andreas’ education combined studies in both science and business.  He earned an undergraduate degree in Industrial Chemistry from State Business School in Berlin, Germany, and a graduate degree in Marketing and Business Management from Berlin’s University of Economics. 

He is a member of the Board of Directors of the non-profit Council of the Americas, and speaks frequently on international health care trends and developments, to select groups of health professionals and industry executives.  Fluent in English, German and Spanish, he is co-author of Strategies for Pharma Management, published in Germany.   Andreas lives with his wife, Corina, a PhD chemist, and two young children in Westchester County, New York.

Richard Johnson, MD, Managing Partner, Hudson Medical Communications

Dr. Richard Johnson is an accomplished life sciences executive who has held executive marketing, corporate development, and operating positions with numerous bio-pharmaceutical and health care services companies. Dr. Johnson is also a prolific entrepreneur, having started seven highly successful life sciences businesses, and the author of several publications and patents.

Dr. Johnson recently founded Hudson Medical Communications (“Hudson”) a full service medical marketing company; MedIQ, a continuing medical education (CME) company; and Hudson BioScience, a late phase clinical research business. In addition, he founded Performax (2004), a physical therapy, rehabilitation, and sports training clinic. While all of these companies remain private, each of them is profitable and on track for a positive exit.

Previously, Dr. Johnson was the CEO of Quintiles Commercialization North America, a group of Quintiles subsidiaries which had combined revenues of over $300 million at the time of his departure. As CEO, Dr. Johnson executed a highly successful turnaround, taking the company from a substantial loss in 2001 to record-setting profit margins within one year. In his role, Dr. Johnson was also involved in investments made by Quintiles’ corporate venture arm, PharmaBio Development. Prior to becoming CEO of Quintiles Commercialization, Dr. Johnson was CEO of Quintiles Integrated Strategic Solutions and Quintiles Medical Communications. Previously, he was a founder of Q.E.D. Communications, a strategic medical communications firm which was acquired by Quintiles Transnational.

Dr. Johnson’s experience also includes senior positions in clinical research, medical education, new product development, and marketing at Lederle Laboratories (now Wyeth Pharmaceuticals), a Fortune 500 pharmaceutical company. During that time, he executed co-promotional deals and licensing agreements, conducted technology assessments and market forecasts, and successfully launched several new products with strong intellectual property claims into highly competitive, multibillion dollar markets. Dr. Johnson formerly practiced internal and critical care medicine and was a General Partner in the Genesis Fund I, a technology venture capital fund located in Houston, Texas.

He earned a bachelor’s degree (Phi Beta Kappa) from New York University and a medical degree from Mount Sinai School of Medicine. In addition, he received graduate business training from Columbia University’s Executive Management Training Program.

Phillip M. Satow

Phillip has more than 35 years of experience in the pharmaceutical industry. He was Executive Vice President of Forest Laboratories, Inc. where he oversaw all marketing and sales functions, was President of Forest Pharmaceuticals and a former member of its Board of Directors. For 15 years as head of sales and marketing for Forest, Phillip built the Company's sales and marketing infrastructure and retired soon after launching Forest's successful anti-depressant, Celexa. Prior to joining Forest, he served for three years as Vice President and General Manager of the Wallace Laboratories Division of Carter-Wallace, Inc. He held a variety of executive positions at Pfizer, Inc. over a 14 year period, including Director of Marketing, Pfizer Laboratories, and Vice President, Pfizer Europe. Most recently Phillip founded JDS Pharmaceuticals LLC along with his son Michael. The company was recently purchased by Noven Inc. Phillip currently serves on the board of directors of Crucell Inc. and Noven Inc., both public companies, holds a B.A. from Columbia College and an M.A. in Economics from Georgetown University.


Emerging Markets Panel

Moderator
Amanda Heron Parsons MD, MBA
Engagement Manager, McKinsey

Amanda Heron is an Engagement Manager in McKinsey’s New York office exclusively focused on the Healthcare Sector.  Since joining the Firm in 2003, she has served the Pharmaceutical & Medical Products practice as well as the Payor/Provider and Global Public Health practices, and has worked in strategy, marketing, product valuation, R&D business plan formulation, and operations improvement. 

Amanda serves on the Board of VIP Community Services and is on the Young Leadership Council of the TOUCH foundation.   Prior to joining McKinsey, Amanda’s work experiences include a Project Specialist position at Theradex, Inc, a CRO in Princeton NJ, focused on preparing drug filings in the Oncology market, and a Business Development position at Warren Pharmaceuticals, a start-up biotech company in Ossining NY, focused on preparing the company’s business plan for the financing rounds.

Amanda earned her M.D. from Columbia University, College of Physicians and Surgeons.  She also holds an MBA from Columbia’s Graduate School of Business, where she majored in Management. Amanda recently took a one-year leave of absence to do her internship in Internal Medicine at Beth Israel Medical Center to become a licensed physician. 

Robert Armstrong
VP External Research, Eli Lilly

Robert W. Armstrong, Ph.D., became vice president of global external research and development for Eli Lilly and Company in November 2006. He previously was vice president of discovery chemistry research. Armstrong's new position will serve to accelerate LRL's ability to access external innovation, including scientific and medical capabilities and capacity, as well as new drug candidates. He is also a member of the senior management council.

Prior to joining Lilly in November 1999, Armstrong had been director and head of small molecule drug discovery at Amgen, Inc.

Born in Texas and raised in Latin America, Armstrong speaks fluent Spanish. He received bachelor of science degrees in chemistry and biochemistry from the University of California at San Diego in 1979 and a doctorate degree in chemistry from Colorado State University in 1984. Upon completion of an NIH postdoctoral fellowship with Yoshito Kishi at Harvard University, he joined the University of California at Los Angeles faculty in 1986 as an assistant professor.

Armstrong's research efforts have concentrated on the areas of total synthesis of natural products, development of synthetic methodology, and synthesis and conformational analysis of natural and synthetic biopolymers, including DNA, peptides, and oligosaccharides. A second area of interest includes the eludication of the mechanism of action of DNA modifying agents and the design of nucleoside modifications as structure-activity probes.

He received an NSF Presidential Young Investigator Award in 1988 and a Sloan Foundation Fellowship in 1990.

David Epstein (’87)
President and CEO, Novartis Oncology

David R. Epstein is President & CEO, Novartis Oncology.  In this position, he is responsible for leading Novartis’ global Oncology Business Unit, one of the world’s top Oncology companies with five key marketed products – Glivec, Femara, Zometa, Sandostatin LAR and Exjade – and a leading pipeline recognized as exceptionally broad and deep.  In 2006, Novartis Oncology’s sales grew 15.5% to $5.9bio and market share grew to 9.8%. 

Epstein currently oversees a staff of more than 4,300 employees operating in over 50 countries.  He is a member of Novartis AG’s Pharma Committee and Pharmaceutical Executive Committee.

Epstein has held a series of positions of increasing responsibility since joining the company as a new product manager with Sandoz in 1989.  Epstein most recently served as CEO, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation & Immunology Business Units in addition to his responsibilities leading Novartis Oncology. He previously served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S and has held several positions in marketing and general management.  During the planning process that resulted in the 1996 merger of Ciba-Geigy Ltd. and Sandoz Ltd., Epstein co-chaired the U.S. and Canadian Pharma Steering Committees as the Integration Officer, North America.  In January 1997, he was promoted to Vice President, Marketing and Sales, Specialty Business Sector, responsible for U.S. business units focused on Oncology and Transplant/Immunology/Tissue Engineering.  Prior to joining the company, he was an associate in the Strategy Practice of consulting firm Booz, Allen and Hamilton.

Epstein holds a B. S. degree in Pharmacy with high honors from Rutgers University College of Pharmacy and an M.B.A. in Finance and Marketing from the Columbia University Graduate School of Business. 

Joseph R. Flicek
Managing Director, Amphion Innovations

Joe Flicek is a Managing Director of Amphion Innovations in their New York Office.  Amphion's business is the formation, financing, management and development of life science and technology companies.  He specializes in taking these new technologies and under-performing assets and leveraging and enhancing their intellectual property and business assets into profitable company building opportunities. Amphion Portfolio Companies are broad-based, proprietary, platform technologies in the areas of pharmacogenomics, nutriceuticals, diagnostics, medical products and related fields, leveraging advances in semiconductors, RFID technologies and life science IT technologies.

He currently serves on the boards of FireStar Software, Inc. and M2M Inc, who are Amphion partner companies.  Mr. Flicek created and established the New Ventures group of the Science & Technology Ventures Office at Columbia University in 1996.  Under his leadership Columbia participated in the formation of over 30 new University spin-outs, four of which are publicly traded. Mr. Flicek is an adjunct faculty member of Columbia University’s Graduate Business School in Entrepreneurship and assists faculty and students in startup businesses through entrepreneurship programs.

David Gershon
Standard & Poor’s Healthcare Economics and Policy Industry Leader www.healthcare-economics.org

Dr. David Gershon has over 20 years experience as a physician, clinical trial investigator, healthcare regulatory attorney, and global healthcare economics and policy advisor with expertise in legislative and regulatory affairs, intellectual property, CMS and private payor pricing/reimbursement, and FDA drug and medical device approval processes. Dr. Gershon currently serves as the Chairman of the National Institute for Healthcare Economics and Regulatory Policy, is a designated Standard & Poor's 'Industry Leader', and serves as advisor to the Goldman Sachs Principal Strategies Group on matters pertaining to global healthcare economics, finance and policy.

Dr. Gershon is recognized for his ability to take a broad look at global legislative, regulatory, and economic changes that affect medical research, drug approval, cost effectiveness, and access to healthcare in the US, Brazil, Russia, India, China, and South Africa and to translate these changing dynamics into models for investment firms and healthcare policy legislators. Of particular interest are large pharmaceutical, biotechnology, generics, and healthcare services companies that either leverage advantages or seek to mitigate damages from these changes.

Over the past 10 years Dr. Gershon has been a senior level advisor for a number of blue chip investment firms, corporations, and legislators including Goldman Sachs, Merrill Lynch, Bain Capital, Schroders, Fidelity Investments, AIG, Publicis, American Express, Bristol-Myers Squibb, GlaxoSmithKline, Texas Pacific Group, Senator John Kerry, Senator John Edwards, and former Attorney General Elliot Spitzer, providing in-depth insights into the increasingly important interaction between medical and scientific advancements and regulatory, legal, and economic changes that affect global healthcare market dynamics and competitive landscapes, including changes in drug discovery, medical research and development, FDA approval processes, pricing, reimbursement, intellectual property, and clinical and commercial market applications for new drugs and devices.

Dr. Gershon has published and lectured widely on healthcare economics, innovation and drug discovery, and healthcare policy. He holds several academic appointments and teaches at business schools in North America and Europe about how scientific innovation and global regulatory changes are driving new business models whose dynamics and creative partnerships are opening new investment opportunities in the pharmaceutical, biotechnology, medical device, healthcare services, and generic pharmaceutical industries.

Dr. Gershon is currently an Adjunct Professor of Healthcare Economics and Policy at Johns Hopkins University, Dept of Advanced Biotechnology/MBA Program; Visiting lecturer of Healthcare Economics and Drug Development at Harvard University; Visiting Scholar Lecturer of Healthcare Economics and Policy at McGill University; and has been a guest lecturer at Oxford University, New York University, and Columbia University.

As part of his social commitment Dr. Gershon is assisting in the design and development of public-private partnerships between policy makers, corporations, foundations, financial firms, and social entrepreneurs that target healthcare disparities and promote innovation in drug R&D, access and distribution.

He is particularly focused on advancing public-private partnerships that develop future leaders who are committed to developing businesses that address healthcare disparities in minority women and children in the U.S. and infrastructure, sustainability and capacity building barriers facing HIV/AIDS, Malaria, and TB care and treatment programs for women and children in Africa and developing countries.

He is writing a book and has designed a series of seminars entitled, "Future Scenarios: Charting a Course in the New Global Healthcare Economy" which defines the role government and public-private partnerships have in shaping healthcare and catalyzing social change in our global economy and provides a practical resource for decision makers to help drive more cost effective, socially responsible utilization of healthcare resources.

Dr. Gershon received his Doctorate in Jurisprudence and Masters Degree in Public Health from Boston University where he specialized in healthcare regulatory law, economics and healthcare policy and his Doctorate in Medicine from McGill University and Post-Doctoral training from New York Presbyterian Medical Center and Memorial Sloan-Kettering Cancer Center. He is the recipient of the Memorial Sloan-Kettering Cancer Center Mayday Fellowship in oncology pain management, the Ciba-Geigy Outstanding Researcher Award, and the Boston University Public Interest Grant.

Joe Shrawder
General Manager, Diagnostic Imaging Performance Technologies

Joe leads a section of GE’s Diagnostic Imaging business focused on value products and solutions for customers around the world.

Performance Technologies includes the GoldSeal refurbished and remanufactured products business and the Primary Care emerging markets business.  The mission of these businesses is to provide high-quality, affordable Diagnostic Imaging systems to customers whose needs are great but whose budgets are not.

Joe has been in GE Healthcare since 2001.  Following an assignment as Six Sigma Quality Leader for the Americas Diagnostic Imaging business, he was appointed as General Manager of GoldSeal in 2003.  In 2005 his role was expanded to include Primary Care for emerging markets as Performance Technologies GM.

Before coming to Healthcare, Joe spent 15 years in a variety of other GE businesses and positions, most recently as Managing Director of GE Quartz Europe from 1999 to 2001 and GE Quartz Asia Pacific Operations GM from 1995 to 1998.

Joe earned a Bachelor of Science in Economics degree from the Wharton School and a Bachelor of Science in Electrical Engineering from the Moore School, both at the University of Pennsylvania, in 1986.